These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 10732861)

  • 1. Reversal of carboplatin resistance in human laryngeal carcinoma cells.
    Vuković L; Osmak M
    Neoplasma; 1999; 46(6):335-41. PubMed ID: 10732861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): mechanisms involved in the resistance.
    Beketić-Oresković L; Osmak M; Jaksić M
    Neoplasma; 1994; 41(3):163-9. PubMed ID: 7935985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha(v)beta(3) Integrin-mediated drug resistance in human laryngeal carcinoma cells is caused by glutathione-dependent elimination of drug-induced reactive oxidative species.
    Brozovic A; Majhen D; Roje V; Mikac N; Jakopec S; Fritz G; Osmak M; Ambriovic-Ristov A
    Mol Pharmacol; 2008 Jul; 74(1):298-306. PubMed ID: 18441044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells.
    Beketic-Oreskovic L; Osmak M
    Cancer Chemother Pharmacol; 1995; 35(4):327-33. PubMed ID: 7828276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine.
    Osmak M
    Neoplasma; 1993; 40(2):97-101. PubMed ID: 8102478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin resistant human laryngeal carcinoma cells are cross resistant to curcumin due to reduced curcumin accumulation.
    Rak S; Cimbora-Zovko T; Gajski G; Dubravčić K; Domijan AM; Delaš I; Garaj-Vrhovac V; Batinić D; Sorić J; Osmak M
    Toxicol In Vitro; 2013 Mar; 27(2):523-32. PubMed ID: 23147641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.
    Li Y; Hu W; Shen DY; Kavanagh JJ; Fu S
    Am J Obstet Gynecol; 2009 Feb; 200(2):177.e1-9. PubMed ID: 19110234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
    Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
    Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
    Deng HB; Adikari M; Parekh HK; Simpkins H
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
    Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
    J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin].
    Rixe O
    Bull Cancer; 2000 Aug; 87 Spec No():7-15. PubMed ID: 11082717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
    Morgan RJ; Synold TW; Gandara D; Muggia F; Scudder S; Reed E; Margolin K; Raschko J; Leong L; Shibata S; Tetef M; Vasilev S; McGonigle K; Longmate J; Yen Y; Chow W; Somlo G; Carroll M; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):283-9. PubMed ID: 15184995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
    Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
    Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
    Lösler S; Schlief S; Kneifel C; Thiel E; Schrezenmeier H; Rojewski MT
    Ann Hematol; 2009 Nov; 88(11):1047-58. PubMed ID: 19301004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP; Reynolds CP
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.
    Osterberg L; Levan K; Partheen K; Helou K; Horvath G
    Cancer Genet Cytogenet; 2005 Dec; 163(2):144-50. PubMed ID: 16337857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.